Literature DB >> 34297116

Body Mass Index and Risk of COVID-19 Diagnosis, Hospitalization, and Death: A Cohort Study of 2 524 926 Catalans.

Martina Recalde1,2, Andrea Pistillo1, Sergio Fernandez-Bertolin1, Elena Roel1,2, Maria Aragon1, Heinz Freisling3, Daniel Prieto-Alhambra4,5, Edward Burn1,4, Talita Duarte-Salles1.   

Abstract

CONTEXT: A comprehensive understanding of the association between body mass index (BMI) and coronavirus disease 2019 (COVID-19) is still lacking.
OBJECTIVE: To investigate associations between BMI and risk of COVID-19 diagnosis, hospitalization with COVID-19, and death after a COVID-19 diagnosis or hospitalization (subsequent death), accounting for potential effect modification by age and sex.
DESIGN: Population-based cohort study.
SETTING: Primary care records covering >80% of the Catalan population, linked to regionwide testing, hospital, and mortality records from March to May 2020. PARTICIPANTS: Adults (≥18 years) with at least 1 measurement of weight and height. MAIN OUTCOME MEASURES: Hazard ratios (HR) for each outcome.
RESULTS: We included 2 524 926 participants. After 67 days of follow-up, 57 443 individuals were diagnosed with COVID-19, 10 862 were hospitalized with COVID-19, and 2467 had a subsequent death. BMI was positively associated with being diagnosed and hospitalized with COVID-19. Compared to a BMI of 22 kg/m2, the HR (95% CI) of a BMI of 31 kg/m2 was 1.22 (1.19-1.24) for diagnosis and 1.88 (1.75-2.03) and 2.01 (1.86-2.18) for hospitalization without and with a prior outpatient diagnosis, respectively. The association between BMI and subsequent death was J-shaped, with a modestly higher risk of death among individuals with BMIs ≤ 19 kg/m2 and a more pronounced increasing risk for BMIs ≥ 40 kg/m2. The increase in risk for COVID-19 outcomes was particularly pronounced among younger patients.
CONCLUSIONS: There is a monotonic association between BMI and COVID-19 diagnosis and hospitalization risks but a J-shaped relationship with mortality. More research is needed to unravel the mechanisms underlying these relationships.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

Entities:  

Keywords:  SARS-CoV-2; adiposity; electronic health records; fatality; hospitalization; obesity

Mesh:

Year:  2021        PMID: 34297116      PMCID: PMC8344917          DOI: 10.1210/clinem/dgab546

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Resistant hypertension and COVID-19: tip of the iceberg?

Authors:  Marijana Tadic; Cesare Cuspidi
Journal:  J Hum Hypertens       Date:  2021-09-10       Impact factor: 2.877

2.  Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50.

Authors:  Junqing Xie; Shuo Feng; Xintong Li; Ester Gea-Mallorquí; Albert Prats-Uribe; Dani Prieto-Alhambra
Journal:  Nat Commun       Date:  2022-03-21       Impact factor: 14.919

Review 3.  Low-grade inflammation, CoVID-19, and obesity: clinical aspect and molecular insights in childhood and adulthood.

Authors:  Giovanna Muscogiuri; Silvia Bettini; Mara Boschetti; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes (Lond)       Date:  2022-04-07       Impact factor: 5.551

4.  Association between obesity and COVID-19 mortality and length of stay in intensive care unit patients in Brazil: a retrospective cohort study.

Authors:  Vitor Barreto Paravidino; Tatiana Henriques Leite; Mauro Felippe Felix Mediano; Rosely Sichieri; Gulnar Azevedo E Silva; Victor Cravo; Alex Balduino; Emmanuel Salgueiro; Bruno Adler Maccagnan Pinheiro Besen; Rodrigo de Carvalho Moreira; Carlos Eduardo Brandão; Danilo Cosme Klein Gomes; Cinthia Almeida Guimarães Assemany; Pedro Cougo
Journal:  Sci Rep       Date:  2022-08-12       Impact factor: 4.996

5.  Causal associations between body fat accumulation and COVID-19 severity: A Mendelian randomization study.

Authors:  Satoshi Yoshiji; Daisuke Tanaka; Hiroto Minamino; Tianyuan Lu; Guillaume Butler-Laporte; Takaaki Murakami; Yoshihito Fujita; J Brent Richards; Nobuya Inagaki
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-03       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.